# Inpatient Treatment of COVID-19 With Anti-Coronavirus Immunoglobulin (ITAC)

> **NCT04546581** · PHASE3 · COMPLETED · sponsor: **University of Minnesota** · enrollment: 593 (actual)

## Conditions studied

- COVID
- COVID-19
- SARS-CoV-2
- SARS (Severe Acute Respiratory Syndrome)

## Interventions

- **BIOLOGICAL:** Hyperimmune immunoglobulin to SARS-CoV-2 (hIVIG)
- **OTHER:** Placebo
- **DRUG:** Remdesivir

## Key facts

- **NCT ID:** NCT04546581
- **Lead sponsor:** University of Minnesota
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-10-08
- **Primary completion:** 2021-05-21
- **Final completion:** 2021-05-21
- **Target enrollment:** 593 (ACTUAL)
- **Last updated:** 2022-04-04

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04546581

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04546581, "Inpatient Treatment of COVID-19 With Anti-Coronavirus Immunoglobulin (ITAC)". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT04546581. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*